These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31189712)

  • 1. Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial.
    Zolla-Pazner S; Gilbert PB
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
    Zolla-Pazner S; deCamp A; Gilbert PB; Williams C; Yates NL; Williams WT; Howington R; Fong Y; Morris DE; Soderberg KA; Irene C; Reichman C; Pinter A; Parks R; Pitisuttithum P; Kaewkungwal J; Rerks-Ngarm S; Nitayaphan S; Andrews C; O'Connell RJ; Yang ZY; Nabel GJ; Kim JH; Michael NL; Montefiori DC; Liao HX; Haynes BF; Tomaras GD
    PLoS One; 2014; 9(2):e87572. PubMed ID: 24504509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
    Rolland M; Gilbert P
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
    Haynes BF; Gilbert PB; McElrath MJ; Zolla-Pazner S; Tomaras GD; Alam SM; Evans DT; Montefiori DC; Karnasuta C; Sutthent R; Liao HX; DeVico AL; Lewis GK; Williams C; Pinter A; Fong Y; Janes H; DeCamp A; Huang Y; Rao M; Billings E; Karasavvas N; Robb ML; Ngauy V; de Souza MS; Paris R; Ferrari G; Bailer RT; Soderberg KA; Andrews C; Berman PW; Frahm N; De Rosa SC; Alpert MD; Yates NL; Shen X; Koup RA; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Rerks-Ngarm S; Michael NL; Kim JH
    N Engl J Med; 2012 Apr; 366(14):1275-86. PubMed ID: 22475592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
    Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ; Kim JH; Excler JL
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.
    Perez LG; Martinez DR; deCamp AC; Pinter A; Berman PW; Francis D; Sinangil F; Lee C; Greene K; Gao H; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; O'Connell RJ; Robb ML; Michael NL; Kim JH; Gilbert P; Montefiori DC
    PLoS One; 2017; 12(7):e0180720. PubMed ID: 28678869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.
    Tolbert WD; Van V; Sherburn R; Tuyishime M; Yan F; Nguyen DN; Stanfield-Oakley S; Easterhoff D; Bonsignori M; Haynes BF; Moody MA; Ray K; Ferrari G; Lewis GK; Pazgier M
    mBio; 2020 Jun; 11(3):. PubMed ID: 32605979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RV144 HIV-1 vaccination impacts post-infection antibody responses.
    Mdluli T; Jian N; Slike B; Paquin-Proulx D; Donofrio G; Alrubayyi A; Gift S; Grande R; Bryson M; Lee A; Dussupt V; Mendez-Riveria L; Sanders-Buell E; Chenine AL; Tran U; Li Y; Brown E; Edlefsen PT; O'Connell R; Gilbert P; Nitayaphan S; Pitisuttihum P; Rerks-Ngarm S; Robb ML; Gramzinski R; Alter G; Tovanabutra S; Georgiev IS; Ackerman ME; Polonis VR; Vasan S; Michael NL; Kim JH; Eller MA; Krebs SJ; Rolland M
    PLoS Pathog; 2020 Dec; 16(12):e1009101. PubMed ID: 33290394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen.
    Wang Q; Dai Y; Sun Z; Su X; Yu Y; Hua C; Xu W; Jiang S; Lu L
    Emerg Microbes Infect; 2017 Nov; 6(11):e102. PubMed ID: 29184156
    [No Abstract]   [Full Text] [Related]  

  • 19. No acquisition: a new ambition for HIV vaccine development?
    Lakhashe SK; Silvestri G; Ruprecht RM
    Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques.
    Devasundaram S; Rosati M; Valentin A; Weiss S; Itri V; Trinh HV; Bear J; Chowdhury B; LaBranche CC; Montefiori D; Ferrari G; Rao M; Kong XP; Zolla-Pazner S; Pavlakis GN; Felber BK
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33087466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.